These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 23357766)

  • 21. Effect of Genetic Variation of
    Dompreh A; Tang X; Zhou J; Yang H; Topletz A; Adu Ahwireng E; Antwi S; Enimil A; Langaee T; Peloquin CA; Court MH; Kwara A
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263072
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future.
    Pasipanodya J; Gumbo T
    Antimicrob Agents Chemother; 2011 Jan; 55(1):24-34. PubMed ID: 20937778
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis.
    van der Laan LE; Garcia-Prats AJ; Schaaf HS; Tikiso T; Wiesner L; de Kock M; Winckler J; Norman J; McIlleron H; Denti P; Hesseling AC
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133558
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and Confirm.
    Gumbo T; Pasipanodya JG; Nuermberger E; Romero K; Hanna D
    Clin Infect Dis; 2015 Aug; 61 Suppl 1():S18-24. PubMed ID: 26224768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intermediate Susceptibility Dose-Dependent Breakpoints For High-Dose Rifampin, Isoniazid, and Pyrazinamide Treatment in Multidrug-Resistant Tuberculosis Programs.
    Zuur MA; Pasipanodya JG; van Soolingen D; van der Werf TS; Gumbo T; Alffenaar JC
    Clin Infect Dis; 2018 Nov; 67(11):1743-1749. PubMed ID: 29697766
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions.
    Kjellsson MC; Via LE; Goh A; Weiner D; Low KM; Kern S; Pillai G; Barry CE; Dartois V
    Antimicrob Agents Chemother; 2012 Jan; 56(1):446-57. PubMed ID: 21986820
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bayesian Population Physiologically-Based Pharmacokinetic (PBPK) Approach for a Physiologically Realistic Characterization of Interindividual Variability in Clinically Relevant Populations.
    Krauss M; Tappe K; Schuppert A; Kuepfer L; Goerlitz L
    PLoS One; 2015; 10(10):e0139423. PubMed ID: 26431198
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of administration of moxifloxacin plus rifampin against Mycobacterium tuberculosis for 7 of 7 days versus 5 of 7 days in an in vitro pharmacodynamic system.
    Drusano GL; Sgambati N; Eichas A; Brown D; Kulawy R; Louie A
    mBio; 2011; 2(4):e00108-11. PubMed ID: 21750119
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis.
    Peloquin CA; Velásquez GE; Lecca L; Calderón RI; Coit J; Milstein M; Osso E; Jimenez J; Tintaya K; Sanchez Garavito E; Vargas Vasquez D; Mitnick CD; Davies G
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559269
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimization of the rifampin dosage to improve the therapeutic efficacy in tuberculosis treatment using a murine model.
    de Steenwinkel JE; Aarnoutse RE; de Knegt GJ; ten Kate MT; Teulen M; Verbrugh HA; Boeree MJ; van Soolingen D; Bakker-Woudenberg IA
    Am J Respir Crit Care Med; 2013 May; 187(10):1127-34. PubMed ID: 23525933
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nonparametric Population Pharmacokinetic Modeling of Isoniazid in Colombian Patients With Tuberculosis.
    Rodriguez CA; Zuluaga AF; Neely MN; Sierra Y; Morales-Gutierrez J; Zapata J; Zapata JD; Naranjo TW; Agudelo Y
    Ther Drug Monit; 2019 Dec; 41(6):719-725. PubMed ID: 31725693
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic Modeling and Optimal Sampling Strategies for Therapeutic Drug Monitoring of Rifampin in Patients with Tuberculosis.
    Sturkenboom MG; Mulder LW; de Jager A; van Altena R; Aarnoutse RE; de Lange WC; Proost JH; Kosterink JG; van der Werf TS; Alffenaar JW
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4907-13. PubMed ID: 26055359
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring.
    Verbeeck RK; Günther G; Kibuule D; Hunter C; Rennie TW
    Eur J Clin Pharmacol; 2016 Aug; 72(8):905-16. PubMed ID: 27305904
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of rifampin in Peruvian tuberculosis patients with and without comorbid diabetes or HIV.
    Requena-Méndez A; Davies G; Ardrey A; Jave O; López-Romero SL; Ward SA; Moore DA
    Antimicrob Agents Chemother; 2012 May; 56(5):2357-63. PubMed ID: 22330931
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Population Pharmacokinetic Models of Antituberculosis Drugs in Patients: A Systematic Critical Review.
    Otalvaro JD; Hernandez AM; Rodriguez CA; Zuluaga AF
    Ther Drug Monit; 2021 Feb; 43(1):108-115. PubMed ID: 32956238
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide.
    Dhillon J; Dickinson JM; Sole K; Mitchison DA
    Antimicrob Agents Chemother; 1996 Mar; 40(3):552-5. PubMed ID: 8851569
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of first-line antituberculosis drugs in HIV-infected children with tuberculosis treated with intermittent regimens in India.
    Ramachandran G; Kumar AK; Bhavani PK; Kannan T; Kumar SR; Gangadevi NP; Banurekha VV; Sekar L; Ravichandran N; Mathevan G; Sanjeeva GN; Dayal R; Swaminathan S
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1162-7. PubMed ID: 25487804
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A semimechanistic pharmacokinetic-enzyme turnover model for rifampin autoinduction in adult tuberculosis patients.
    Smythe W; Khandelwal A; Merle C; Rustomjee R; Gninafon M; Bocar Lo M; Sow OB; Olliaro PL; Lienhardt C; Horton J; Smith P; McIlleron H; Simonsson US
    Antimicrob Agents Chemother; 2012 Apr; 56(4):2091-8. PubMed ID: 22252827
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients.
    Ruslami R; Nijland HM; Alisjahbana B; Parwati I; van Crevel R; Aarnoutse RE
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2546-51. PubMed ID: 17452486
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systematic Analysis of Hollow Fiber Model of Tuberculosis Experiments.
    Pasipanodya JG; Nuermberger E; Romero K; Hanna D; Gumbo T
    Clin Infect Dis; 2015 Aug; 61 Suppl 1():S10-7. PubMed ID: 26224767
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.